All In Biotech

Investigational drug · Phase 3

Tacabrutideg

Also called: BGB-16673

Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Lymphocytic Leukemia, B-cell Malignancy, Small Lymphocytic Lymphoma.

Phase 3

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

6

6 still active

All registered trials

11

Any phase or sponsor naming "Tacabrutideg"

First trial start

2021

Sep 13, 2021

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Tacabrutideg", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Chronic Lymphocytic Leukemia
  • B-cell Malignancy
  • Small Lymphocytic Lymphoma
  • Non-Hodgkin Lymphoma
  • Mantle Cell Lymphoma
  • Waldenström Macroglobulinemia
  • Marginal Zone Lymphoma
  • Follicular Lymphoma
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • DLBCL Unclassifiable

Approved drugs for the same conditions: Chronic lymphocytic leukemia · Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Hematology and blood cancers

Largest trials

Live from ClinicalTrials.gov: studies naming "Tacabrutideg" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 11 on PubMed

Also in development for Chronic Lymphocytic Leukemia

  • APG-2575lisaftoclaxPhase 310 trials

    Ascentage Pharma Group Inc. · CLL/SLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

  • MK-2140Zilovertamab Vedotin, VLS-101Phase 39 trials

    Merck & Co. · Diffuse Large B-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, B-cell Acute Lymphoblastic Leukemia

  • NemtabrutinibMK-1026, ARQ 531Phase 36 trials

    Merck & Co. · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma

  • KRT-232NavtemadlinPhase 34 trials

    Kartos Therapeutics, Inc. · Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma

  • NX-5948bexobrutidegPhase 33 trials

    Nurix Therapeutics, Inc. · B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

  • CLR 131I-131-CLR1404, Iopofosine I 131 single dosePhase 32 trials

    Cellectar Biosciences, Inc. · Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia

  • EmavusertibCA-4948Phase 22 trials

    Curis, Inc. · Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from BeOne Medicines (BeiGene).

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.